Tools, Biomarkers Needed to Identify Immune-Related Toxicities

Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer

FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer

We Have Not ‘Come a Long Way, Baby’: Dr. Alan Blum on Smoking Cessation and Prevention

FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

Expanded Indication for Pafolacianine Imaging Agent in Lung Cancer Approved by FDA

Anti-FSP Antibodies May Predict ICI Outcomes in Lung Cancer

Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer

FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer

We Have Not ‘Come a Long Way, Baby’: Dr. Alan Blum on Smoking Cessation and Prevention

FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

Expanded Indication for Pafolacianine Imaging Agent in Lung Cancer Approved by FDA

Anti-FSP Antibodies May Predict ICI Outcomes in Lung Cancer

Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer

FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer

We Have Not ‘Come a Long Way, Baby’: Dr. Alan Blum on Smoking Cessation and Prevention

FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

Expanded Indication for Pafolacianine Imaging Agent in Lung Cancer Approved by FDA

Anti-FSP Antibodies May Predict ICI Outcomes in Lung Cancer

Related Content

Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer

Findings from a study suggest that anti-frameshift peptide antibodies may also predict incidence of immune-related adverse effects in patients with lung cancer following immune checkpoint inhibitor therapy.

FDA Approves Imaging Agent Designed to Target Tumors in Lung Cancer

Podcast

ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.

We Have Not ‘Come a Long Way, Baby’: Dr. Alan Blum on Smoking Cessation and Prevention

“Upon activating a fluorescent lamp, the cancer tissue glows very brightly, like stars against a black sky, and enables us to see exactly where the tumor tissue was.”

FDA Grants Novel Liquid Biopsy Assay Breakthrough Device Designation to Detect Lung Cancer

Podcast

Smoking cessation and relapse prevention expert Alan Blum, MD, discusses how oncologists and other clinicians can and should play a larger role in tobacco control.

OncobiotaLUNG, a novel liquid biopsy that detects lung cancer, now has a breakthrough device designation from the FDA.

Expanded Indication for Pafolacianine Imaging Agent in Lung Cancer Approved by FDA

OncobiotaLUNG, a novel liquid biopsy that detects lung cancer, now has a breakthrough device designation from the FDA.

An expanded indication for pafolacianine as an imaging agent for patients with lung cancer has been approved by the FDA based on findings from the phase 3 ELUCIDATE trial.